Evaluation of Lipid-Stabilised Tripropionin Nanodroplets as a Delivery Route for Combretastatin A4 by Mico, V et al.
This is a repository copy of Evaluation of Lipid-Stabilised Tripropionin Nanodroplets as a 
Delivery Route for Combretastatin A4.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/116230/
Version: Accepted Version
Article:
Mico, V, Charalambous, A orcid.org/0000-0001-5895-3697, Peyman, SA 
orcid.org/0000-0002-1600-5100 et al. (4 more authors) (2017) Evaluation of 
Lipid-Stabilised Tripropionin Nanodroplets as a Delivery Route for Combretastatin A4. 
International Journal of Pharmaceutics, 526 (1-2). pp. 547-555. ISSN 0378-5173 
https://doi.org/10.1016/j.ijpharm.2017.05.009
© 2017 Published by Elsevier B.V. This manuscript version is made available under the 
CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ 
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Accepted Manuscript
Title: Evaluation of Lipid-Stabilised Tripropionin
Nanodroplets as a Delivery Route for Combretastatin A4
Author: Victoria Mico Antonia Charalambous Sally A.
Peyman Radwa H. Abou-Saleh Alexander F. Markham P.
Louise Coletta Stephen D. Evans
PII: S0378-5173(17)30401-5
DOI: http://dx.doi.org/doi:10.1016/j.ijpharm.2017.05.009
Reference: IJP 16657
To appear in: International Journal of Pharmaceutics
Received date: 15-3-2017
Accepted date: 4-5-2017
Please cite this article as: Victoria Mico, Antonia Charalambous, Sally A. Peyman,
Radwa H. Abou-Saleh, Alexander F. Markham, P. Louise Coletta, Stephen D. Evans,
Evaluation of Lipid-Stabilised Tripropionin Nanodroplets as a Delivery Route for
Combretastatin A4, <![CDATA[International Journal of Pharmaceutics]]> (2017),
http://dx.doi.org/10.1016/j.ijpharm.2017.05.009
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
Page 1 of 26
Ac
ce
pte
d M
an
us
cri
pt
Evaluation of Lipid-Stabilised Tripropionin
Nanodroplets as a Delivery Route for Combretastatin
A4
Victoria Mico,a Antonia Charalambous,b Sally A. Peyman,a Radwa H.
Abou-Saleh,a c Alexander F. Markham,b P. Louise Coletta,b and Stephen D.
Evansa∗
aSchool of Physics and Astronomy, University of Leeds, LS2 9JT, UK.
bLeeds Institute of Biomedical and Clinical Sciences, St James’s University Hospital,
University of Leeds, LS9 7TF, UK.
cBiophysics Group, Department of Physics, Faculty of Science, Mansoura University,
Egypt
∗ Postal address: School of Physics and Astronomy E.C. Stoner Building Room 8.34
(Level 8) University of Leeds Leeds, LS2 9JT, UK, Telephone number: 0113 343 3852.
Corresponding author e-mail: s.d.evans@leeds.ac.uk
Abstract
Lipid-based nanoemulsions are a cheap and elegant route for improving
the delivery of hydrophobic drugs. Easy and quick to prepare, nanoemul-
sions have promise for the delivery of different therapeutic agents. Although
multiple studies have investigated the effects of the oil and preparation con-
ditions on the size of the nanoemulsion nanodroplets for food applications,
analogous studies for nanoemulsions for therapeutic applications are limited.
Here we present a study on the production of lipid-stabilised oil nanodroplets
(LONDs) towards medical applications. A number of biocompatible oils were
used to form LONDs with phospholipid coatings, and among these, squalane
and tripropionin were chosen as model oils for subsequent studies. LONDs
were formed by high pressure homogenisation, and their size was found to
decrease with increasing production pressure. When produced at 175 MPa,
all LONDs samples exhibited sizes between 100−300 nm, with polydispersity
index PI between 0.1− 0.3. The LONDs were stable for over six weeks, at 4
◦C, and also under physiological conditions, showing modest changes in size
(< 10%). The hydrophobic drug combretastatin A4 (CA4) was encapsulated
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in tripropionin LONDs with an efficiency of approximately 76%, achieving
drug concentration of approximately 1.3 mg/ml. SVR mouse endothelial cells
treated with CA4 tripropionin LONDs showed the microtubule disruption,
characteristic of drug uptake for all tested doses, which suggests successful
release of the CA4 from the LONDs.
Keywords: Drug Delivery, Nanoemulsion, Combretastatin
1. Introduction1
The pharmaceutical industry produces many new potential therapeutic2
agents that have poor water solubility. Many of these hydrophobic agents3
show promising results during in vitro studies, when administered dissolved4
in solvents like DMSO. However, when undergoing pre-clinical testing, the5
hydrophobicity of drugs often makes them difficult to deliver, resulting in re-6
duced bioavailability and efficacy.[1]. A multitude of different routes for hy-7
drophobic drug encapsulation have been proposed,[2] from micelles[3, 4, 5] to8
porous nanoparticles.[2, 6] Among these methods, sub-micron emulsions, or9
nanoemulsions,[7] are a versatile option for the encapsulation and delivery of10
poor water soluble compounds.[8] Nanoemulsions consist of nanometer-sized11
oil droplets dispersed in water; the oil is generally assumed to be insoluble in12
the water phase. The adsorption of a surfactant in the oil-water interface al-13
lows for the existence of the nanodroplets, and helps preventing nanodroplet14
coalescence.[9] The use of nanoemulsions for hydrophobic drug delivery re-15
lies on the encapsulation of the therapeutic agent within the oil core of the16
nanodroplets. High-energy methods for the production of nanoemulsions in-17
clude ultrasonication [10] and high pressure homogenisation[11, 12, 13, 14],18
resulting in nanodroplets below 300 nm in diameter. Such nanodroplets are19
particularly relevant for drug delivery as they are able to achieve good pene-20
tration though small capillaries as well as uptake across tissue.[15] There are21
several factors that influence the size of the nanodroplets within an emulsion.22
For the specific case of high-pressure homogenisation, the production pressure23
plays a crucial role as it determines the efficiency in dispersing the oil into the24
water phase. The literature about this topic is extensive, but it has mostly25
focused in nanoemulsions aimed at the food industry.[16, 17] The nature of26
the surfactant used to stabilise the nanoemulsions is also known to affect the27
size of the nanodroplets.[18] For example, increasing concentrations of PEG28
in the surface of lipid-stabilised nanoemulsions has been reported to reduce29
2
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the size of the droplets.[19] Therapeutic nanoemulsions have been success-30
fully prepared using a range of different biocompatible surfactants, including31
Tween,[20] polyethylene glycol[21] and lipids.[22, 23, 24, 14, 25] Nevertheless,32
lipid shells are of particular relevance for drug delivery systems, as phospho-33
lipids are cheap, easy to handle and are versatile, i.e. to include different34
ligands for nanodroplet functionalisation to enhance biocompatibility and35
permit attachment of targeting agents such as antibodies.[26, 27, 19] In ad-36
dition to the production pressure and the chosen surfactant, the viscosity37
of the oil has been observed to influence the size of the nanoemulsion nan-38
odroplets prepared using different methods.[28, 29] Lower viscosity oils have39
been observed to produce smaller nanodroplets than higher viscosity oils such40
as long chain triglycerides. For example, Sanguansri and co-workers observed41
a size difference of around 33% when comparing nanodroplets prepared with42
peanut oil (∼ 57 mPa·s at 25 ◦C) and hexadecane (2.66 mPa·s at 25 ◦C).[30]43
This effect is attributed to the enhancement of the droplet deformability44
when using lower viscosity oils, which results in a more efficient dispersion45
of the oil in the water phase.46
To date, nanoemulsions have been used in wide range of treatments, such47
as antiviral,[31] and antimalarial[22, 32]. Furthermore, a number of anti-48
cancer drugs have been delivered to tumours using nanoemulsions.[33, 21, 14]49
For example, Dacarbazine encapsulated in soybean oil nanodroplets was50
found to have an increased efficacy when administered in vivo.[34] Com-51
bretastatin A4 (CA4) belongs to a group of vascular disrupting agents which52
selectively cause rapid shut down of established tumour vasculature.[35, 36].53
CA4 has a high binding affinity to tubulin, which leads to morphological54
changes of the endothelial cells cytoskeleton. In vivo treatments with CA455
are impaired by the toxicity and poor water solubility of the drug. Efforts56
to improve treatments with CA4 have led to the development of the more57
soluble produg combretastatin A4 phosphate (CA4P). CA4P has been evalu-58
ated as a monotherapy in a number of Phase I clinical trials, with a reported59
number of adverse side effects including nausea, vomiting, tumour pain and60
more severe cases of acute coronary syndrome.[37, 38] There are ongoing61
Phase II/III clinical trials assessing CA4P in combination with other drugs62
such as Bevacizumab.[39]. Although converting CA4 to the water soluble pro63
drug CA4P permits delivery its toxicity still leads to a number of undesired64
side effects. Therefore there is an unmet clinical need for the development65
of a vehicle that is able to deliver compounds like CA4 in more targeted66
strategies.67
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Various developments have been made towards enhancing the delivery of68
CA4 through its incorporation in liposomes. Liposomal formulations rely on69
the incorporation of CA4 in the lipid bilayer and therefore they are greatly70
restricted in the amount of CA4 that can be loaded.[40, 41] Bibby and co-71
workers studied the effect of CA4 delivered in a 10% DMSO/oil emulsion in72
vivo. They found severe vascular shut-down and tumour growth delay as a73
result of the treatment with 150 mg/kg of CA4 administered in this way.[42]74
However DMSO is not an ideal solvent for the injection of poor water soluble75
drugs due to its adverse side effects.76
Here we report the encapsulation and in vitro delivery of CA4 in lipid-77
stabilised oil nanodroplets (LONDs) (Figure 1). LONDs are formed in a78
two-step homogenisation process that progressively refines the size distribu-79
tion of the colloidal solution. This process includes a blending step, and80
homogenisation under high pressure. To optimise the formation of LONDs,81
and to determine the best oil to deliver CA4, a number of biocompatible oils82
were screened. LONDs were prepared using seven different oils, and their83
size, stability and concentration determined. Of these, squalane and tripro-84
pionin were found to successfully form LONDs and were chosen as model oils85
for further studies. Size differences were observed in LOND samples prepared86
under different pressures, and also between the different oils. Squalane and87
tripropionin LONDs were stable for at least six weeks when kept at 4 ◦C,88
and for > 2 h at 37 ◦C. CA4 was successfully encapsulated in tripropionin89
LONDs. In vitro evaluation of CA4 in SVR mouse endothelial cells at es-90
calating doses revealed collapsed microtubule structures characteristic of the91
activity of the CA4. This suggests successful drug release and intracellular92
uptake of drug from LONDs, which is a promising step towards effective and93
safe treatments with CA4 in vivo .94
2. Methods95
2.1. Materials96
All lipids were purchased from Avanti Lipids (USA), including 1palmitoyl-97
2-oleoyl-sn- glycero- 3-phosphocholine (POPC), 1,2- distearoyl-sn- glycero- 3-98
phosphocholine (DSPC), 1,2-distearoyl-sn-glycero- 3-phosphoethanolamine-99
N-[methoxy (polyethylene glycol)- 2000] (PEG2000-DSPE) and 1,2-distearoyl-100
sn-glycero- 3-phosphoethanolamine-N-[biotinyl (polyethylene glycol)- 2000]101
(biotin-PEG2000-DSPE). Fluorescently tagged 1,2-dioleoyl-sn- glycero- 3-102
phosphoethanolamine (DOPE), Atto590 DOPE and Atto488 DOPE, were103
4
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obtained from Atto-TEC (Germany). All oils were purchased from Sigma-104
Aldrich (UK), including squalane, squalene, triacetin, olive oil, isoamyl ac-105
etate (IA), tripropionin and eicosapentaenoic acid (EPA). Combretastatin106
A4 (CA4) was obtained from Sigma (UK). The primary mouse monoclonal107
anti-β-tubulin antibody was also obtained from Sigma (UK). Secondary anti-108
bodies biotin-labelled polyclonal rabbit anti-mouse was obtained from DAKO109
(UK) and fluorescein-isothiocyanate-labelled Avidin D was obtained from110
Vector Laboratories (UK). Antibody diluent ready to use reagent and Pro-111
long Gold with DAPI were obtained from Thermo Fisher Scientific (UK).112
2.2. LONDs formation113
LONDs are emulsion droplets stabilised with phospholipids. LONDs were114
formed in a two-step homogenisation process of oil-in-water mixtures contain-115
ing lipid. All lipid mixtures were initially dissolved in a chloroform-methanol116
mixture (1 : 1) and then dried under nitrogen for at least 30 min. The117
lipid shell was tuned for the different oils, informed by preliminary opti-118
misation on the production (data not shown). Hence, and unless otherwise119
stated, POPC + 5% biotin-PEG2000-DSPE was used for stabilising squalane120
LONDs, whereas DSPC + 20% Cholesterol + 5% biotin-PEG2000-DSPE was121
used for the preparation of tripropionin LONDs; these lipid shell combina-122
tions enhanced the stability of the LONDs and reduced premature coales-123
cence. When required, fluorescence tracking of LONDs was performed by124
incorporating 0.1mol% Atto590-DOPE or Atto488-DOPE to the lipid mix.125
The lipids were re-suspended in 0.7 ml (φ = 0.07) of oil by vortexing. The oil126
fraction was kept constant during the experiments. Occasionally the dried127
lipid took longer to disperse in the oil, and an additional bath-sonication step128
was required. For samples encapsulating drugs or drug mimics, the com-129
pound was solubilised in the oil to the desired concentration before adding it130
to the lipids. The homogenisation process began with a blending step using131
the rotor-stator system Polytron PT1300 D (Kinematica AG, Switzerland).132
Polytron blending of the sample was carried out at 12500 rpm for 10 min,133
at 40 ◦ C and atmospheric pressure. LONDs formation was completed in134
a high-pressure homogeniser EmulsiFlex-C5 (Avestin Europe GmbH, Ger-135
many) for 20 min. The pressure was varied between 35− 175 MPa to study136
the dependence of LONDs size with the production pressure. Other than the137
LOND samples used to study the effect of the production pressure, LONDs138
were prepared under 175 MPa unless otherwise stated. Excess lipid and non-139
encapsulated oil were removed from the LONDs solution by filtration using140
5
Page 6 of 26
Ac
ce
pte
d M
an
us
cri
pt
a KrosFlow Research IIi Tangential Flow Filtration System (SpectrumLabs141
Europe, The Netherlands) and 60 kDa Mini-Discover12 pore size column142
(WaterSep, USA) for at least 2 h.143
2.3. LONDs size and concentration144
Filtered LONDs were sized by Dynamic Light Scattering (DLS) using145
a Zetasizer Nano ZSP (Malvern Instruments, UK). For the measurements,146
10 µl of the LOND sample were dissolved in 1 ml of PBS in an ordinary147
disposable cuvette. Three measurements of the sample distribution were148
performed, each of which consisted of 10 − 17 runs as determined by the149
Malvern ZetaSizer Software. DLS was also used to study the stability of150
LONDs size over time, with storage at 4 ◦C between measurements. The151
stability of LONDs at 37 ◦C was also investigated using DLS. In this case,152
the sample was kept at 37 ◦C for 2 h and measurements of its size distribution153
were taken every 15 min. The sample was gently shaken between measure-154
ments to avoid creaming (or sedimentation). The size of LOND samples155
was alternatively determined by nanoparticle tracking analysis (NTA) using156
a NanoSight instrument (Malvern Instruments, UK). This device was also157
used to determine the concentration of LOND samples. NTA relies on the158
detection of light scattered by sub-micron sized particles, which is used to159
calculate individual diffusion coefficients and estimate their size.[43] Samples160
containing around 106 LONDs/ml were used for the measurements with the161
NanoSight instrument (normally involving a 1 : 106 dilution of the origi-162
nal sample). All data regarding LOND size and concentration was analysed163
using Origin 9 (OriginLab Corporation, USA).164
2.4. Transmission electron microscopy165
Transmission electron microscopy (TEM) images of LONDs were taken166
using a JEM1400, 120 kV instrument (JEOL, USA). Samples for TEM167
imaging were prepared by depositing 15 µl of the LONDs samples (1011168
LONDs/ml, in PBS) on a carbon coated grid. The solution was left on the169
grid for 30 s, and the excess liquid dried out using blotting paper. Samples170
were negatively stained using uranyl acetate by dropping 15 µl of uranyl ac-171
etate (1%) on the grid and incubating for 15 s, after which the excess liquid172
was removed with blotting paper. Images were analysed using ImageJ.173
6
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2.5. Encapsulation efficiency of CA4 in LONDs174
The concentration of CA4 in LOND preparations was determined by com-175
paring their UV-VIS absorption to a calibration curve for CA4 dissolved in176
tripropionin. A Lambda 35 UV-VIS Spectrometer (Perkin Elmer, USA) was177
used to record absorption spectra of the samples. All absorption spectra were178
recorded between 200−700 nm. The peak absorption for CA4 diluted in the179
oil (not encapsulated) lies around 309 nm. To measure the amount of CA4180
encapsulated in the LONDs, 10 µl of LONDs solution was dispersed in 990181
µl of DMSO. In this way, the LONDs are broken and their contents released,182
eliminating light scattering from intact LONDs in the solution, which can183
cause detection issues.184
2.6. In vitro cell culture185
SVR mouse pancreatic islet endothelial cells transformed with Ras onco-186
gene, were cultured in high glucose Dulbecco’s modified Eagle’s medium187
(DMEM) supplemented with 5% (v/v) foetal calf serum (FCS) at 37 ◦C and188
5% CO2. SVR cells were grown to 80 − 90% confluence, trypsinised and189
seeded in µ-slide VI (ibidi, Germany) at a density of 3× 105 overnight after190
which they were treated with CA4 tripropionin LONDs . All treatments and191
sequential staining were carried out directly in the µ-slide. Escalating doses192
of CA4 tripropionin LONDs (4 mM stock concentration) were added to SVR193
cells in fresh media for 2 h at 37 ◦C. Following the 2 h treatment the cells194
were washed with PBS and fixed with 4%(v/v) paraformaldehyde in PBS195
for 10 min and permeabilised with 0.1% Triton X-100 in PBS for 5 min. To196
reduce non specific binding the cells were blocked with antibody diluent for197
5 min at room temperature. Immunofluorescence staining was performed for198
β-tubulin 1:500 in antibody diluent for 2 h at room temperature. The cells199
were then washed with PBS and incubated with biotin-labelled polyclonal200
rabbit anti-mouse 1:200 in antibody diluent for 1h at room temperature201
followed by fluorescein isothiocyanate-labelled Avidin D 1:250 in antibody202
diluent for 1h at room temperature. The µ-slide was mounted with Prolong203
Gold and DAPI (4,6-diamidino-2-phenylindole) to visualise nuclei. Fluores-204
cent images were acquired using a ZEISS Axioimager Z1 microscope (Carl205
Zeiss Microscopy, USA) with AxioVision software at x40.206
2.7. Quantification of CA4 effect207
To quantitate the extent of disruption to microtubules caused by CA4208
tripropionin LONDs, fluorescence images of control untreated cells and cells209
7
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treated with CA4 tripropionin LONDs were taken (n = 5). The length of210
10 microtubules from five randomly selected cells were measured in each of211
the five images (total of 250 microtubules). Image J and GraphPAD were212
used to measure the microtubules and data plotting, respectively. Statistical213
analysis was carried using a Mann-Whitney test.214
3. Results and discussion215
3.1. Preparation of LONDs with candidate oils216
LONDs were prepared in a two-step homogenisation process of an oil-in-217
water and phospholipids mixture. The crude emulsions was initially blent in218
a rotor-stator system for around 10 min to create a rough dispersion of the oil219
into the water phase, and to dissolve big lipid agglomerates. This mixing step220
was followed by high pressure homogenisation for 20 min in an Emulsiflex.221
In this device, the crude emulsion was forced though a homogenising nozzle,222
where it experienced great mechanical stress for a short time. Figure 2 shows223
the size distribution of squalane LONDs after processing under high pressure,224
as measured with DLS, as an example. The high pressure homogenisation225
step was performed at 175 MPa, and reduced the size distribution of the226
sample giving a polydispersity index (PI) lower than 0.3 (figure 2b). The227
average size of the LONDs was (165±5) nm. After filtration, the average size228
of the sample increased slightly to (188 ± 11) nm (figure 2). This apparent229
size change of about 12% was accompanied by a slight increase in distribu-230
tion width, as indicated by the increase of the full width at half maximum231
(FWHM). This perhaps indicates that the filtration process gave rise to mild232
sample coalescence.233
A number of biocompatible oils were screened to determine their ability to234
form LONDs stabilised with POPC + 5% biotin-PEG2000-DSPE and at 175235
MPa. Table 1 summarises the results obtained for the different oils, including236
the size and concentration of the LONDs, where applicable. Isoamyl acetate237
(IA) and eicosapentaenoic acid (EPA) did not produce stable LONDs, thus238
no further experiments were performed with these. The concentration of239
triacetin LONDs was found to be lower than that of LONDs prepared with240
any other oil. This was attributed to the higher solubility of triacetin in wa-241
ter. Among all of the oils tested, tripropionin LONDs exhibited the smaller242
size, and also the highest concentration. LONDs prepared with squalane,243
squalene or olive oil produced LONDs of similar size, PI and concentra-244
tion. Pure oils were chosen over blends such as olive oil, whose composition245
8
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strongly depends on its production environment and manufacturer. The size246
of the LONDs prepared with different candidate oils remained stable for a247
period of more than six weeks, at 4 ◦C. Details for the case of tripropionin248
and squalane LONDs are provided below. Squalane and tripropionin were249
used as oils for the optimisation of LONDs production, in order to compare250
LOND production with oils of different density and viscosity.251
252
3.2. Dependence of LONDs size and concentration on production pressure253
Control over the size of the LONDs is important for reproducible pharma-254
cokinetic/pharmacodynamic studies. Furthermore, the size of nanocarriers255
greatly influences their biodistribution and bioavailability.[15] The produc-256
tion of LONDs was monitored as a function of the homogenisation pressure257
using two different oil/shell combinations: i) squalane LONDs stabilised with258
POPC, and ii) tripropionin LONDs stabilised with DSPC + 20mol% Choles-259
terol + 5mol% biotin-PEG2000-DSPE. Size measurements of both LOND260
samples prepared under 35, 70, 105, 140 and 175 MPa were performed using261
DLS and NanoSight. Figure 3 shows the changes in the size distribution of262
the two LOND samples prepared under different pressures, as determined by263
DLS. In the case of squalane, the average size of the droplets d was fitted264
to the relationship d = C · P−b, where P is the pressure applied at the ho-265
mogenising nozzle in the Emulsiflex. The parameter b is determined by the266
turbulent regime existent in the homogenising device, which depends mostly267
on the size of the appliance,[44] whereas C depends on efficiency of the droplet268
disruption.[45] Through the fitting of the sizing data for squalane LONDs,269
b was found to be b = (0.70 ± 0.06). This value is in agreement with previ-270
ous observations, which reported values of b between 0.6 − 0.75 for regimes271
dominated by inertial or shear forces, respectively.[46, 45] In the case of272
tripropionin LONDs, their size was found to reduce with increasing produc-273
tion pressure. It is also interesting to note that the size change undergone by274
tripropionin LONDs between 35 and 175 MPa was of around 25%, whereas275
the size change for squalane LONDs was of about 70%. This is thought276
to relate primarily to the differences in viscosity between tripropionin and277
squalane, as viscosity is known to influence the size of the nanodroplets in a278
nanoemulsion.[30]279
Upon preparation of a nanoemulsion, the number of nanodroplets formed280
is generally assumed to be determined by the oil volume fraction φ. Although281
this assumption is true in general, non-negligible solubility of the oil in water282
9
Page 10 of 26
Ac
ce
pte
d M
an
us
cri
pt
could result in a reduced number of nanodroplets, since the disperse phase283
could partially dissolve in the continuous prior to surfactant stabilisation.284
The concentration and size of LONDs prepared under different pressures285
(35, 70, 105, 140 and 175 MPa) were determined with the NanoSight instru-286
ment. Figure 4 shows concentration change in LOND samples as a function287
of the production pressure, for squalane (a) and tripropionin LONDs (b).288
Squalane LONDs show a rapid decrease in their size distribution with in-289
creasing pressure. The size reduction coincides with an increase in the num-290
ber of LONDs in the solution. The concentration reached a steady value at291
around (2.2 ± 0.4) × 1013 ml−1. This is in agreement with the predicted in-292
crease in the efficiency of the oil breakage upon increase of the shear forces at293
the homogenising nozzle (i.e. increasing production pressure). These values294
are, within experimental error, consistent with the theoretical value for the295
concentration of LONDs calculated though size considerations for φ = 0.07296
(∼ 2 × 1013 LONDs/ml). In the case of tripropionin LONDs (figure 4b),297
increasing production pressures (35−145 MPa) resulted in distribution sizes298
changes of around 4%. Sample processing under 175 MPa for 10 min re-299
sulted in a significant size reduction (∼ 16%), accompanied by an increase300
of the LOND concentration (∼ 53%). As expected, the concentration of the301
the tripropionin LOND sample prepared under 175 MPa ((1.4± 0.1)× 1014302
LONDs/ml) is in agreement with the theoretical value for the concentration303
of LONDs, based on LONDs dimension and oil volume fraction (φ = 0.07),304
1.3× 1014 LONDs/ml.305
3.3. Stability of LONDs306
The stability of LONDs as a function of time was followed by monitoring307
the size distribution of LOND samples using DLS. Sample agglomeration or308
degradation was expected to translate into changes in the size distribution,309
such as broadening of the original size distribution and increases in the PI.310
Two different studies were performed: i) to determine the stability of LONDs311
during six weeks, and ii) to determine the stability of LONDs at 37 ◦C in312
in vitro conditions for 2 h. There was an interest in monitoring the stability313
of LONDs for a time period that would resemble the time required for the314
LONDs to initially reach the target site and accumulate over time in an in315
vivo setting. Hence the choice of a 2 h period for this experiment. The316
temperature conditions in this experiment aimed to better resemble those to317
which the LONDs would be exposed to in vivo.318
10
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As reflected in table 1, LONDs prepared from all the candidate oils showed319
good stability over a six weeks period. During this time, the PIs were < 0.3320
in all cases. As an example of the type of data recorded, figure 5a shows the321
size variation of squalane and tripropionin LONDs over six weeks. Each ex-322
perimental point was produced averaging three DLS runs. This graph shows323
a maximum size variation of around 16% for squalane LONDs, and around324
15% for tripropionin LONDs. This small variation of the LONDs diameter325
over time suggests good stability of the LONDs against agglomeration and326
coalescence. Figure 5b shows the size variation for squalane and tripropionin327
LONDs during 2 h, and incubated 37 ◦C more consistent with conditions in328
vitro. The sizes of both LOND types did not change, showing good stabil-329
ity under these conditions. This suggests that LONDs are suitable vehicles330
for the delivery of hydrophobic compounds in vivo and have an excellent331
potential to enhance the delivery of poor water soluble drugs.332
3.4. TEM imaging of LONDs333
TEM was used to image LOND samples. Figure 6 shows the TEM images334
of squalane and tripropionin LONDs. Squalane LONDs appeared as globular335
structures ranging 100 − 300 nm, with an average size of 111 nm (n = 187,336
with a standard deviation of the sample σ = 85 nm). In contrast, tripropionin337
LONDs appeared to lose their structure under vacuum conditions in TEM,338
and exhibited a shell appearance. These LONDs were found to have an339
average size 89 nm (n = 71, with a standard deviation of the sample σ = 23340
nm). A small discrepancy was observed between the TEM and DLS sizing341
of both squalane and tripropionin LONDs. This was expected and it is342
attributed to the different conditions under which the samples are studied343
in one and another techniques (i.e. the sample is dried for TEM imaging,344
whereas the hydrodynamic radius of the colloids are measured by DLS).345
3.5. Encapsulation of CA4 in LONDs346
Drug delivery using nanoemulsions, and LONDs in particular, rely on347
drug encapsulation within their structure. It is generally accepted that the348
drug is encapsulated within the oil core of the nanoemulsions, and that its349
lipophilicity directly affects its release from the nanodroplets and therefore350
its biodistribution.[47] It is also known that the polarity of a therapeutic com-351
pounds defines its solubility in oils.[32, 48] CA4 is a largely polar molecule352
with poor water solubility. However, its polarity made it difficult to dissolve353
in squalane, as it is a saturated, non-polar oil. Triacetin and tripropionin354
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were profiled as more suitable oils for the preparation of LONDs encapsulat-355
ing CA4, as the polarity of the oil enhanced the solubility of CA4. Tripropi-356
onin was chosen over triacetin, in light of its reduced water solubility. The357
concentration of the drug encapsulated in LONDs was determined by mea-358
suring its absorption in the UV-VIS. The calibration curve produced for the359
CA4 in tripropionin is presented in the supplementary. The encapsulation360
efficiency of CA4 in tripropionin LONDs was approximately 76%, with 1270361
µg/ml in the final LOND sample.362
3.6. CA4 tripropionin LONDs cause microtubule disruption363
To qualitatively and quantitatively assess LOND-based drug delivery,364
CA4 tripropionin LONDs were used to treat SVR endothelial cells. The cells365
were treated with escalating concentrations of CA4 tripropionin LONDs from366
2 − 100 nM for 2 h at 37 ◦C. Figure 7 is a represe tative panel of images367
showing the effect caused by CA4 tripropionin LOND exposure. CA4 tripro-368
pionin LONDs caused complete microtubule disruption evident in all SVR369
cells treated with 40−100 nM, with microtubules appearing as a uniform flu-370
orescence surrounding the cells nuclei. At concentrations lower than 2 − 20371
nM, some short microtubules could be seen. Control untreated SVR cells372
showed normal microtubule structures.373
To quantitate the effect on SVR cells and to evaluate the effect caused374
to microtubules by CA4 tripropionin LOND treatment, the lengths of the375
cellular microtubules were measured. Figure 8 shows the average microtubule376
length for the different treatment concentrations. Compared to control, cells377
treated with doses of CA4 tripropionin LONDs between 4 − 100 nM are378
significantly different ****P < 0.001. A significant difference *P< 0.024379
was observed in the smallest concentration of 2 nM. It should be noted that380
the exact mechanism of drug uptake is unclear however the fact that CA4381
tripropionin LONDs at 37◦C are stable suggests that the lipid membrane of382
the LONDs fuses with cell membranes leading to drug release or the LONDs383
are endocytosed leading to intracellular release of CA4.384
4. Conclusion385
We have carried out a systematic study on the formation of lipid-stabilised386
oil nanodroplets (LONDs) with a range of biocompatible oils, towards med-387
ical applications. LONDs are formed in a two-step process that includes388
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blending using a rotor-stator system and high pressure homogenisation. Pro-389
duction pressure has been found to be a factor affecting the size of the390
LONDs, an it also affects LONDs concentration in the final sample. LOND391
samples exhibit excellent stability over time and under different conditions.392
The hydrophobic therapeutic drug Combretastatin A4 (CA4) was encapsu-393
lated in tripropionin LONDs with an efficiency of around 76%. Preliminary394
studies on LOND-based delivery of this compound to SVR cells have shown395
successful drug release from the LONDs, attending at the effect on cellular396
microtubules by the encapsulated CA4. Tripropionin LONDs show promis-397
ing results for the delivery of CA4 in vitro, and they hold exciting potential398
for facilitating the delivery of the compound in vivo. We anticipate that399
studies concerned with the use of CA4 in anticancer combination therapies400
will benefit from the enhancement of the delivery routes for CA4.401
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Figure 1: Schematic of a lipid-stabilised oil nanodroplet (LONDs). Hydrophobic drugs,
such as CA4, are contained in the oil core of the LONDs, which is stabilised by a lipid
monolayer.
Figure 2: Changes in the size distribution of a squalane LONDs sample: a) after high
pressure homogenisation (at 175 MPa), with average size (165±5) nm and b) after sample
cross-filtration, mode size (188± 11) nm. The width of the distribution (full width at half
maximum, FWHM) is indicated in the figures.
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Figure 3: DLS sizing of squalane and tripropionin LOND samples prepared at different
pressures. Squalane LONDs were stabilised with POPC, and the shell of the tripropionin
LONDs was DSPC + 20% Cholesterol + 5% biotin-PEG2000-DSPE. The lines show fits
to the data.
Figure 4: Nanoparticle Tracking Analysis (NTA) measurements on a) squalane LONDs
stabilised with POPC and b) tripropionin LONDs stabilised with DSPC + 20% cholesterol
+ 5% biotin-PEG2000-DSPE. The graph shows the changes in size and concentration of
the LONDs in the solution, and the data points were fitted as a guide to the eye.
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Figure 5: a) Size change of squalane and triacetin LONDs over a six week period, stored
at 4 ◦C, and measured using DLS. b) Size change of squalane and triacetin LONDs at
37 ◦ over 2 h, as measured by DLS. Experimental points in both graphs were produced
averaging three size measurements on the same sample.
Figure 6: TEM images of LONDs. a) Squalane LONDs stabilised with POPC + 5%
biotin-PEG2000-DSPE. b) Tripropionin LONDs stabilised with DSPC + 20% Cholesterol
+ 5% biotin-PEG2000-DSPE. Both samples were prepared under at 175 kPa.
16
Page 17 of 26
Accepted Manuscript
Figure 7: CA4 tripropionin LONDs disrupt microtubules in vitro. SVR mouse endothelial cells were treated with CA4
tripropionin LONDs at a dose escalation range between 2 nM to 100 nM for 2h at 37 ◦C follwed by washing and fixing with 4%
paraformaldehyde. Immunofluorescence staining of β-tubulin was carried out. Prolong Gold with DAPI was used to mount
and visualise the nuclei. The results show at higher doses of 100 nM to 40 nM CA4 released from the LONDs causes complete
microtubule disruption leading to a uniform fluorescence around the nuclei. Lower doses of 20 nM to 2 nM show a varying
lengths of microtubule filaments. Untreated cells were used as control where normal microtubules can be seen. Scale bar 50
µm.
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Figure 8: Quantification of microtubule lengths following CA4 tripropionin LOND expo-
sure of 2 h at 37 ◦C. A total of 250 microtubule filaments were measured with Image
J from five images taken from different positions on the ibidi µ-Slide. Error bars were
calculated by Mann-Whitney test. *P< 0.0240 , ****P< 0.0001. Results shown as media
with interquartile range.
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Table 1: LOND preparation and stability for different oil types and a POPC + 5% biotin-PEG200-DSPE* shell.
Oil Solubility in Viscosity Density Lipid Diameter a Concentration Stability
H2O (g/L) at 20
◦C (cP ) (g/cm3) stabilised (nm) (ml−1) (weeks)
Squalane - 12 0.805 Yes 165 1013 > 6
Squalene 0.124×10−3 11 0.858 Yes 133 1013 -
Olive oil - 85 0.918 Yes 191 - > 6
Triacetin 61 23 1.160 Yes 250 1011 > 6
Tripropionin 0.003 7 1.082 Yes 100 1014 > 6
IA 2 7.2 0.876 No - - -
EPA 0.284×10−3 35 0.923 No - - -
∗ Tripropionin LONDs shell was 75mol% DSPC + 5mol% Cholesterol + 5mol% PEG2000-DSPE. Olive oil, IA and EPA had POPC shells.
a Two-step preparation process and cross filtration. Emulsiflex pressure was 175 kPa in all cases. Sizing data on this table was measured with DLS. Concentration
data for squalane and squalene LONDs was obtained with NTA, and Qnano was used to obtain the concentration of triacetin LONDs.
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